Femasys Inc. develops biomedical products for women’s reproductive health, with news centered on fertility treatment, fallopian tube assessment, and non-surgical permanent birth control. Its portfolio includes FemaSeed intratubal insemination, FemaSeed Complete for in-office fertility care, FemVue for ultrasound-based fallopian tube evaluation, FemBloc permanent birth control, and related diagnostic products such as FemChec.
Recurring updates cover product commercialization in OB/GYN settings, international distribution and market access, regulatory approvals outside the United States, U.S. clinical and regulatory development for FemBloc, reimbursement-related developments, financing, operating results, and governance changes.
Femasys CEO Kathy Lee-Sepsick met with the White House’s Gender Policy Council to discuss the company's reproductive health products and the future of women's health in the U.S. The meeting supported the President's Executive Order on Advancing Women’s Health Research and Innovation, highlighting funding needs for women’s healthcare initiatives. Femasys, an Atlanta-based biomedical company, offers innovative in-office therapeutic and diagnostic products. The company will display its products, including FemBloc® and FemaSeed®, at the ACOG Annual Meeting in San Francisco from May 17-19, 2024.
Femasys Inc. (NASDAQ: FEMY) announces financial results for Q1 2024, highlighting positive topline data for FemaSeed infertility treatment, commercial procedures, appointment of Richard Spector as Chief Commercial Officer, and initiation of pivotal trial for FemBloc. The company is well-positioned to commercialize its infertility portfolio, with cash to fund operations into H2 2025. Financially, R&D expenses increased, sales decreased, and net loss grew, but the company believes its cash and equivalents will suffice. Current assets, liabilities, and stockholders' equity are detailed in the PR.
Femasys Inc. (Nasdaq: FEMY) announces the expansion of its commercial management team, adding experienced professionals to drive strategic initiatives and launch efforts at the 2024 ACOG Meeting. The team will focus on the infertility portfolio, led by FemaSeed®, a cost-effective and safe approach for artificial insemination. The company aims to address the record-low birth rates in the U.S. by providing innovative solutions to women's healthcare needs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.